(Q43754196)

English

Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

Y Yamada

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

K Shirao

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

A Ohtsu

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

N Boku

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

I Hyodo

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

H Saitoh

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Y Miyata

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

T Taguchi

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

1 August 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1133-1137

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011680507956

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011680507956

7 January 2021

based on heuristic

inferred from DOI database lookup

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011680507956

7 January 2021

based on heuristic

inferred from DOI database lookup

Promotion of microtubule assembly in vitro by taxol

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011680507956

7 January 2021

based on heuristic

inferred from DOI database lookup

Taxol: a novel investigational antimicrotubule agent

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011680507956

7 January 2021

based on heuristic

inferred from DOI database lookup

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011680507956

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011680507956

7 January 2021

based on heuristic

inferred from DOI database lookup

Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011680507956

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011680507956

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypersensitivity reactions from taxol

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011680507956

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011680507956

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011680507956

7 January 2021

based on heuristic

inferred from DOI database lookup

An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011680507956

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. BMS-181339 Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011680507956

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1011680507956

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43754196&oldid=2103055340"